Neurology-Focused Alector Downgraded On Failed Alzheimer's Study, BofA Securities Highlights Lack Of Catalysts
Alector's AL002 misses primary endpoint in Alzheimer's trial. BofA downgrades stock, cuts price target, and highlights near-term challenges.
Alector downgraded to Underperform at BofA after Alzheimer’s trial miss
As previously reported, BofA downgraded Alector (ALEC) to Underperform from Neutral with a price target of $1, down from $9, after ALOO2 missed ...
Vigil Neuroscience initiated with an Outperform at William Blair
William Blair initiated coverage of Vigil Neuroscience (VIGL) with an Outperform rating and $18.67 fair value estimate. Vigil is developing a ...
Vigil Neuroscience: Down On A Competitor's Failure
Vigil Neuroscience's stock dropped after Alector's AL002 failed in Alzheimer's, raising concerns about VG-3927's efficacy.
PipelineReview.com6d
Alector Announces Results from AL002 INVOKE-2 Phase 2 Trial in Individuals with Early Alzheimer’s Disease and Provides Business Update
SOUTH SAN FRANCISCO, CA, USA I November 25, 2024 I Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering novel, genetically ...
Alector: Bleak Prospects After Alzheimer's Failure
Alector has significant cash reserves but faces high cash burn, with no immediate catalysts and uncertain prospects for its ...